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Abstract 
A 60-year-old man with neovascular glaucoma due to diabetic retinopathy received an 
intravitreal injection of 1.25 mg bevacizumab (IVB) followed by extensive panretinal 
photocoagulation in the right eye. The anterior segment neovascularization regressed within 
10 days after IVB. One and a half months later, the patient underwent gastrectomy for stage 
IIIb gastric cancer. Two months later, he was started on S-1 orally (100 mg/day for 48, 26, 
and 32 consecutive days in the first, second, and third treatment cycle, respectively). The 
interval between the first and second treatment cycle was 20 days and between the second 
and third cycle it was 24 days. The patient developed anemia and diarrhea. At the end of the 
second S-1 cycle, cystoid macular edema developed in the right eye, although diabetic 
retinopathy and neovascular glaucoma were stable. Macular edema persisted for 5 months 
despite another IVB, and disappeared 3 months after termination of S-1 therapy. The time 
course of the magnitude of macular edema correlated well with the severity of anemia. The 
macular edema was possibly associated with anemia, which is a major side effect of S-1. 
Further studies are warranted to investigate the relationship between anemia and macular 
edema in patients with diabetic retinopathy. 
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Introduction 
S-1 is an oral antineoplastic agent consisting of the fluorouracil (5-FU) prodrug 
tegafur combined with two modulators, 5-chloro-2,4-dihydroxypyridine and potassium 
oxonate. S-1-based chemotherapy is the standard treatment of advanced gastric cancer 
in Japan [1]. Although S-1 is designed to be more active and less toxic than intravenous 
5-FU with fewer gastrointestinal side effects, ocular surface and lacrimal complications 
have been reported [2, 3]. In contrast, retinal adverse events were not found through a 
literature search. We present a case with diabetic retinopathy and neovascular 
glaucoma that developed cystoid macular edema during postoperative adjunctive 
chemotherapy of S-1 for advanced gastric cancer. The macular edema was possibly 
associated with anemia, a major side effect of S-1 [4]. 
Case Presentation 
A 60-year-old man was referred to our department for the treatment of neovascular glaucoma due 
to diabetic retinopathy in the right eye. Visual acuity was 0.4 in the right eye, and there was no light 
perception in the left eye. Intraocular pressures were 12 and 18 mm Hg in the right and left eyes, 
respectively, under maximum antiglaucoma medications. Slit-lamp examination disclosed marked iris 
rubeosis, a mostly open angle with prominent neovascularization in the right eye, a scarred bleb after 
trabeculectomy and less active anterior segment neovascularization in the left eye, and nuclear 
cataract in both eyes. Fundus examination revealed scattered blot hemorrhages, cotton wool spots 
and scattered laser scars (fig. 1a). Glaucomatous optic disc cupping was present in both eyes, and the 
optic disc in the left eye was totally pale. Macular edema which was examined by optical coherence 
tomography (OCT; Stratus OCT, Carl Zeiss Meditec, Dublin, Calif., USA) was absent in both eyes (fig. 
1b, c). 
An intravitreal injection of 1.25 mg bevacizumab (IVB), an antibody against vascular endothelial 
growth factor (VEGF), followed by extensive panretinal photocoagulation was performed in the right 
eye, which resulted in regression of anterior segment neovascularization within 10 days after IVB. 
Off-label use of bevacizumab was approved by the Institutional Review Board of the Kanazawa 
University Graduate School of Medical Science, Kanazawa, Japan. Informed consent was obtained from 
the patient regarding treatment of the right eye after thorough discussion, especially concerning 
bevacizumab. One and a half months later, he underwent gastrectomy for stage IIIb gastric cancer. 
Two months after gastrectomy, the patient underwent phacoemulsification and intraocular lens 
implantation in the right eye, with subsequent improvement in vision to 0.9. Prior to cataract surgery, 
a second IVB was performed to prevent postoperative macular edema. Nine days after cataract 
surgery, he was started on S-1 orally (100 mg/day for 48, 26, 32 consecutive days in the first, second, 
and third treatment cycle, respectively). The interval between the first and second treatment cycle 
was 20 days, and between the second and third cycle it was 24 days. 
At the end of the second cycle, 3 months after cataract surgery, vision in his right eye decreased to 
0.4. Emergence of cystoid macular edema in the right eye was confirmed by OCT (fig. 1d–f). Since we 
could observe the edema clearly in the OCT images, and diabetic retinopathy and neovascular 
glaucoma were stable, we did not perform fluorescein angiography as a follow-up examination of the 
edema. Diffuse superficial keratitis developed in the right eye, which was successfully treated using a 
disposable soft contact lens and sodium hyaluronate eye drops. Macular edema persisted for 5 
months despite another IVB (fig. 1g–i). Macular edema disappeared 3 months after termination of S-1 
therapy (fig. 1j–l). Vision in the right eye returned to 0.9. The time course of the 1-mm central retinal 
thickness correlated well with that of the severity of anemia (fig. 2). No recurrence of macular edema 
was observed for more than 1 year.  
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Discussion 
Cystoid macular edema developed in a patient with diabetic retinopathy and 
neovascular glaucoma. Macular edema is a common complication of diabetic 
retinopathy and VEGF is believed to contribute to its pathogenesis. Highly elevated 
intraocular concentration of VEGF was reported in eyes with neovascular glaucoma [5]. 
This patient received panretinal photocoagulation and cataract surgery, each of which 
may have induced macular edema. IVB was recently reported to suppress macular 
edema associated with these interventions in patients with diabetic retinopathy [6, 7]. 
In this case, bevacizumab was injected prior to both therapies. Given that macular 
edema emerged 6 and 3 months after initiation of panretinal photocoagulation and 
cataract surgery, respectively, these procedures were unlikely a primary initiator of 
macular edema. Fundus examination also excluded the presence of other retinopathies 
that can cause macular edema, such as retinal vein occlusion. Worsening of diabetic 
retinopathy and neovascular glaucoma did not occur during the follow-up period. Thus, 
no intraocular findings could explain the emergence of macular edema. 
The patient underwent gastrectomy, and macular edema occurred during the period 
of postoperative S-1 chemotherapy. The patient also developed diffuse superficial 
keratitis. The ocular surface damage by S-1 is thought to be a direct toxicity of the drug 
in the tear film [3]. However, no studies, including a clinical trial of intravitreal 
injections, have shown any 5-FU-induced morphological alterations in the retina [8]. 
Therefore, macular edema was unlikely to be caused by a direct toxicity of 5-FU. 
Systemic side effects of S-1 include myelosuppression, gastrointestinal toxicity, and 
skin reactions. This patient developed anemia and diarrhea during S-1 treatment. 
Hemoglobin concentration decreased below 10 g/dl, which corresponds to grade 2 
anemia, according to the National Cancer Institute Common Toxicity Criteria for 
Adverse Events (version 2.0). The incidence of grade 2 or more anemia was 33% in 
patients using S-1 in a large-scale trial of postoperative adjuvant chemotherapy for 
advanced gastric cancer conducted in Japan [4]. It is noteworthy that the time course of 
the severity of anemia correlated well with that of the magnitude of macular edema. It 
is plausible that retinal hypoxia due to diabetic retinopathy became worse as a 
consequence of S-1-induced anemia, which resulted in the emergence of macular 
edema. 
Regarding drug-induced macular edema in patients with diabetes, 
thiazolidinediones, a class of drug that binds the peroxisome proliferator-activated 
receptor-γ to reduce insulin resistance in type 2 diabetes, have been reported to be 
associated with macular edema [9]. This patient had no history of taking this drug. 
Macular edema is thought to be caused by drug-induced systemic fluid retention [9]. 
However, mild anemia is also a major side effect of thiazolidinediones [10]. Further 
studies are warranted to investigate the relationship between anemia and macular 
edema in patients with diabetes. 
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Fig. 1. Fundus photographs and OCT images of the right eye. a–c Macular edema was absent at the first 
visit to our department. d–f Cystoid macular edema emerged at the end of the second S-1 cycle. g–i 
Macular edema persisted 1 month after an intravitreal injection of 1.25 mg bevacizumab. j–l Macular 
edema disappeared 3 months after termination of S-1 therapy. a, d, g, j Fundus photographs. b, e, h, k 
Horizontal line scans through the fovea. c, f, i, l Macular thickness maps. 
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Fig. 2. Relationship between the time course of anemia and macular edema in the right eye. Upper 
graph: hemoglobin concentration. The vertical double-headed arrow indicates the normal range. 
Lower graph: the 1-mm central retinal thickness in OCT images. # Gastrectomy. * Cataract surgery. 
§ Intravitreal injections of 1.25 mg bevacizumab. Boxes in the horizontal axis indicate the periods of 
S-1 treatment. Horizontal axes of both graphs indicate months after the first visit to our department. 
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